BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Viroblock SA Reports a 99% Boost of Efficacy of Facemasks Against H5N1


5/5/2009 11:50:34 AM

PLAN-LES-OUATES, Switzerland, May 5 /PRNewswire/ -- Viroblock SA announces that its antiviral products boosts the efficacy of facemasks by at least 99.0%, i.e. 100 times better and a peak performance of 1000 times, against avian influenza virus H5N1. Disposable facemasks are thus far not very effective against viruses, such as influenza, whose sizes are 0.02 to 0.3 microns.

Its patented technology (VCCD Tech) potentially inactivates all families and strains of enveloped viruses, like human, avian and swine Influenzas, SARS, AIDS, Ebola and smallpox viruses. VCCD Tech uses a mechanism of action that greatly limits the development of any viral resistance.

The test involved flowing air contaminated with the aerosolized avian Influenza H5N1 virus through a set of pre-impregnated facemasks. Airstreams that passed through facemasks (percolation) were then analyzed for the presence of residual infectious virus. Performance was compared to non-impregnated facemasks. This series of tests was performed at Retroscreen Virology Ltd, a recognized world leader in the research and testing of antiviral compounds and vaccines.

"We are very pleased by the excellent results obtained during the last 6 months. In-vivo campaigns (ferrets) have recently demonstrated the efficacy of VCCD Tech as an antiviral intranasal spray and this latest series of tests shows the stunning performance of our formulations on facemasks. Meanwhile the most recent ex-vivo screening campaigns prove its efficacy on additional viruses.

"H5N1 is just one of a number of emerging viruses such as SARS, and lately the swine flu, which represent a genuine threat across the globe. Viroblock has the technology platform to contribute to the development of new and innovative antiviral countermeasures, such as facemasks to protect not only frontline and government staff such as nurses, doctors, paramedics, firemen and police officers, but also the general public. I believe that Viroblock has all the assets to become a key player in pandemic influenza preparedness efforts," comments CEO Thierry Pelet.

"All these results establish the broad spectrum of action of VCDD Tech against enveloped viruses and the flexibility in its deployment. Our technology is a breakthrough for inactivating enveloped viruses and their strains; I am convinced that we have not yet exploited all its potential. I am pleased to be part of an outstanding team that works tirelessly to develop and fully exploit our technology platform," added Francois Gilardoni, member of the Board.

About Viroblock SA

Viroblock SA is a Swiss start-up founded in 2005, which has become a pioneer and world leader in the blocking virus transmission technology. Viroblock was founded by Dr. Donald F. H. Wallach who was a worldwide expert in artificial and bio-membranes, and non-phospholipid vesicles.

Its patented VCCD technology is suitable for solid supports, colloidal suspensions, emulsions, and aerosol sprays.

CONTACT: Contact: Dr. Thierry Pelet, Chief Executive Officer, Viroblock
SA, Phone: +41-22-884-8344, E-Mail: info@viroblock.com



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES